학술논문
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
Document Type
Article
Author
Abou-Alfa, Ghassan; Alfonso, Jorge Adeva; Aglietta, Massimo; Baron, Ari; Beg, Muhammad; Aguirre, Paula Carrasco; Chen, Eric; Cheng, Ying; Gracián, Antonio Cubillo; Dahan, Laetitia; De Braud, Filippo; Fenocchio, Elisabetta; Gbolohon, Olumide; Gillmore, Roopinder; Jary, Marine; Javle, Milind; Jiang, Yixing; Kang, Jung Hun; King, Gentry George; Kundranda, Madappa; Layos, Laura; Li, Daneng; Liang, Tingbo; Lonardi, Sara; Marathe, Omkar; Mondaca, Sebastian; Martin, Andrés J. Muñoz; Park, Joon Oh; Pazo Cid, Roberto; Fernandez, Paula Ribera; Rimassa, Lorenza; Alonso, Rosa Rodriguez; Sadeghi, Saeed; Scott, Aaron; Tan, Benjamin; Tougeron, David; Yan, Qiang; Yin, Xiaoyu; Zhao, Haitao; Harding, James J ; Fan, Jia ; Oh, Do-Youn; Choi, Hye Jin; Kim, Jin Won; Chang, Heung-Moon; Bao, Lequn; Sun, Hui-Chuan; Macarulla, Teresa; Xie, Feng; Metges, Jean-Phillippe; Ying, Jie'er; Bridgewater, John; Lee, Myung-Ah; Tejani, Mohamedtaki A; Chen, Emerson Y; Kim, Dong Uk; Wasan, Harpreet; Ducreux, Michel; Bao, Yuanyuan; Boyken, Lisa; Ma, Jiafang; Garfin, Phillip; Pant, Shubham
Source
In The Lancet Oncology July 2023 24(7):772-782
Subject
Language
ISSN
1470-2045